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1. Introduction 
Coronary artery disease (CAD) remains the leading cause of death across the globe 
(Rosamond et al., 2008). Although it was thought in the past that coronary artery disease 
was a disease of the Western world, it is now well known that the developing countries are 
not spared of the risk (see Figure 1). In fact, recent studies have indicated that in the next 
decade or so, 80% of the deaths from cardiovascular diseases are projected to occur in 
developing countries (Yusuf et al., 2001). It is also quite interesting that despite tremendous 
advances in cardiovascular medicine, myocardial infraction and sudden death are still the 
initial presentation in half of the patients with coronary artery disease. In the last few 
decades, cardiac developments have improved the care, and prolonged longevity of patients 
who suffer an acute coronary syndrome. Unfortunately, the efforts in primary prevention of 
cardiovascular disease have not quite paralleled the advances in secondary prevention 
(Rosamond, 2008).  
Given the silent nature of the disease and the significant repercussions, it is imperative for 
physicians to identify at risk individuals early, and implement effective primary prevention 
of coronary artery disease. Even when selecting pharmacotherapy for cholesterol and blood 
pressure management, guidelines rely on the patients risk to dictate the intensity of 
treatment. Thus, cardiovascular risk assessment is the first and most crucial step in the 
management of the cardiovascular patient. Such risk assessment has traditionally been 
guided by clinical tools such as the Framingham Risk Score (FRS) from the Framingham 
Heart Study in the United States, or the Systemic Coronary Risk Evaluation, “SCORE” from 
European studies on cardiovascular risk assessment (Conroy et al., 2003). Additionally, 
clinicians use laboratory markers, chiefly total and LDL cholesterol to assess an individual’s 
risk.  
Developing a stellar risk determinant requires thorough understanding of the process of 
atherosclerosis. Atherosclerosis is an ongoing process that occurs through out the life of an 
individual. We now know that plaque ruptures rather than gradually developing coronary 
stenoses are the culprits in acute coronary syndromes. A variety of chemokines are involved 
in the process, and an individual’s genetic susceptibility to these enzymes plays a vital role 
in determining who is at risk for plaque ruptures and cardiac events (KJ Williams et al., 
2008). A truly preventative and comprehensive risk assessment algorithm should detect 
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asymptomatic atherosclerosis by making room for inflammatory markers capable of 
predicting downstream coronary events. Although lipid panels and Framingham scores 
provide an assessment of an individual’s overall risk, neither of them specifically indicates 
arterial inflammation or an individual’s susceptibility for plaque rupture, the two 
fundamental culprits in acute coronary syndromes. The goal of medical research is to 
combine clinical criteria along with pertinent laboratory values and atherosclerosis imaging 
to generate an inclusive risk assessment tool for patients. Another desirable attribute of this 
tool is that it should go above and beyond the barriers of gender and ethnicity, and be 
applicable to a global population. This chapter discusses the role of novel risk factors, 
focusing mainly on coronary calcium scoring (CCS), while touching upon high sensitivity C 
reactive protein (CRP), and apolipoproteins in cardiovascular disease. It is important to 
understand where the traditional risk factors fall short of risk prediction, and where these 
novel markers could improve our assessment.  
 
Adapted with permission from American Heart Association: Heart disease & stroke statistics—2010 
update. A report from the American Heart Association, Dallas, Tex, 2010, American Heart Association. 
Fig. 1. Age-adjusted rates of death from coronary heart disease (per 100,000 population) 
among men aged 35 to 74 in selected countries. 
1.1 Atherosclerosis an inflammatory process 
Atherogenesis in blood vessels has been described to occur in four major steps. The first step 
is initiation of endothelial activation. Lipoproteins play a key role in this step. During this 
stage, the intima of susceptible arteries areas (those subjected to hemodynamic stresses) gets 
infiltrated by atherogenic lipoproteins including low-density lipoproteins (LDL), very low 
density lipoproteins (VLDL) and other triglyceride rich lipoproteins (TGRL). Under 
www.intechopen.com
 
Vascular Inflammation: A New Horizon in Cardiovascular Risk Assessment 
 
105 
appropriate genetic and environmental triggers, the modified lipoproteins release 
inflammatory signals to activate endothelial cells. Recently, the role of platelets has been 
explored in endothelial activation. Platelets release inflammatory mediators such as 
interleukin 1 beta(IL-1), CD40L, which lead to endothelial activation. This is particularly 
pronounced in patients with diabetes, hypertension, obesity, dyslipidemia, and in smokers 
(Vasina et al 2010, Gasparyan et al 2011). The activated endothelial cells express intracellular 
cell adhesion molecules such as (ICAM)-1 and glycoprotein I-B (GpIB), which promote 
platelet adhesion and activation. The activated endothelial cells also release chemoattractant 
and adhesion molecules such as monocyte chemoattractant protein (MCP-1) and vascular 
cell adhesion molecule1 (VCAM-1). These molecules attract phagocytic cells such as 
monocytes in to the intima of the vessel wall. These monocytes ingest the modified 
lipoproteins and turn in to foam cells. In the mean while platelets release platelet derived 
growth factor (PDGF), which attracts smooth muscle cells (Hopkins & RR Williams, 1981).  
During the promotion phase, lipoprotein infiltration continues in proportion to their plasma 
levels. The growth or necrosis of the plaque is controlled by a balance between lipoprotein 
entry, foam cell formation and reverse cholesterol transport out of the plaque (Tabas, 2002). 
During the progression phase, macrophages secrete matrix metalloproteinases (MMPs) that 
weaken the fibrous cap of the plaque. Additionally, Interferon-γ secreted by activated T cells 
strongly inhibits collagen synthesis (Libby, 2009). The weakened cap allows cholesterol 
crystals to erode through the endothelium, causing encroachment of the plaque in to the 
vessel lumen. Thus, inflammation appears to be the key to plaque destabilization and 
rupture (Crisby et al., 2001) (see Fig 2). 
 
Modified with permission from Hopkins, P. Molecular Biology and Genetics of Atherosclerosis. 
Preventative Cardiology. Elseviers/Saunders, c2011.  
Fig. 2. Atherosclerotic plaque destabilization, rupture and calcification. 
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Shearing stress on the vessel wall from uncontrolled hypertension, contributes to 
endothelial activation. This stress, in conjunction with other risk factors determines plaque 
composition with regards to percentage of fibrous versus lipid components (Cheng et al., 
2006). Calcium starts to appear inside plaques during the healing and remodeling phase of 
ruptured plaques. Higher the intimal calcium in a blood vessel, more are the number of 
prior silent or manifest plaque rupture events inside it (Sangiorgi et al., 1998).  
2. Assessment of atherosclerosis and cardiovascular risk 
Risk identification and stratification for a clinician begins with an office based assessment of 
the patient. The presence of CAD/CAD equivalents such as diabetes, peripheral vascular 
disease automatically places the patient in the high-risk category, needing no further 
stratification. In the absence of CAD equivalents, risk factors such as hypertension, cigarette 
smoking, low HDL, family history of premature CAD are considered. When two or more 
risk factors are present, clinicians currently use risk assessment algorithms such as 
Framingham Heart Study from the United States or from the Prospective Cardiovascular 
Münster (PROCAM) study in Germany, or the European risk prediction system called 
SCORE (Systemic Coronary Risk Evaluation). These algorithms project an individual’s 10 
year, absolute risk for cardiovascular events such as myocardial infarction (MI), cardiac 
death (see Table 1). It should be noted that the derived risk is short to intermediate term, 
and not a lifetime assessment. The cumulative effects of risk factors depend on the duration 
of an individual’s exposure to them. 10-year risk may not be sufficient enough to manifest 
such effects. It is a known fact that the incidence of coronary artery disease increases 
exponentially with age (McDermott, 2007; Petersen et al., 2005). Thus, if one decides to go by 
10-year prediction algorithms alone, a significant number of patients with coronary artery 
disease would be classified as low risk. Their lifetime risk would be missed because of the 
myopic nature of the algorithm.  
Long-term risk assessment is particularly relevant for younger patients, in whom initiation 
of healthy lifestyle modifications and treatment may be delayed or even avoided due to lack 
of risk awareness. To evade such neglect, the author recommends that physicians should get 
in to the habit of estimating the lifetime risk. This paradigm has not yet been enforced by 
clinical guidelines. Lifetime risk assessment is generally performed using the modified 
technique of survival, and Kaplan Meyer analysis (Lloyd-Jones et al., 2006). These analyses 
although useful for statistical purposes, are fairly complicated and may not be feasible for 
day-to-day use in a clinical setting. The alternative is to assess long-term cardiac risk using 
markers for subclinical atherosclerosis. The traditional risk assessment algorithms suffer 
from a complete lack of such markers (both biochemical and imaging). Among chemical 
markers, high sensitivity CRP and apolipoprotein analysis may herald early atherosclerosis. 
On the imaging front, carotid intimal medial thickness (CIMT) and coronary calcium scoring 
are two indicators of subclinical atherosclerosis that can be easily measured. CIMT is 
reviewed elsewhere in this book. The author will focus on coronary calcification in the 
sections to follow. 
2.1 Assessment of coronary artery calcium 
As discussed before, the presence of calcium speaks for plaque rupture and healing events 
within the vessel wall. Calcification of plaques is an active process involving deposition of 
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hydroxyapatite crystals, as opposed to simple mineral precipitation. The concept of 
visualizing coronary calcium was first proposed in the early 1980's by a team of physicists at 
University of California, San Francisco. They invented the Electron Beam Tomography 
(EBT) scanner, formerly known as the Ultrafast Computed Tomography (CT) (UIC, 2011). It 
was only in the early 1990's, after years of rigorous testing at major medical centers around 
the world, that medical institutions began offering Coronary Artery Calcification Scans to 
the general public. 
 
*CHD includes history of myocardial infarction, unstable angina, stable angina, coronary artery 
procedures (angioplasty or by-pass surgery), or evidence of clinically significant myocardial ischemia. 
†CHD risk equivalents include clinical manifestations of non-coronary forms of atherosclerotic disease 
(peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic 
attacks or stroke of carotid origin or greater than 50% obstruction of a carotid artery]), diabetes, and 2 
risk factors with 10-year risk for hard CHD less than 20%. ‡Major risk factors include cigarette smoking, 
hypertension (BP greater than or equal to 140/90 mm Hg or on antihypertensive medication), low HDL 
cholesterol (less than 40 mg/dL), family history of premature CHD (CHD in male first-degree relative 
less than 55 years; CHD in female first-degree relative less than 65 years), and age (men greater than or 
equal to 45 years; women greater than or equal to 55 years). §Almost all people with 0 to 1 risk factor 
have a 10-year risk less than 10%, and 10-year risk assessment in people with 0 to 1 risk factor is thus 
not necessary.  
Modified with permission from Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical 
trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 
2004; 110: 227–39 (16).  
BP blood pressure; CHD coronary heart disease; HDL high-density lipoprotein.  
Table 1. Absolute Risk Categories as per the National Cholesterol Education Program 
(NCEP) Update, 2004  
In the present day, there are two modalities for detection of coronary artery calcification. 
Traditionally, EBT scans were used for this purpose. However, with the development of 
Multidetector Computed Tomography (MDCT) scanners within the last decade, MDCT has 
become increasingly popular for the same purpose. Imaging continuously moving 
structures such as the heart can be fairly challenging. The scan has to be gated off the 
patient’s electrocardiogram (ECG). Coronary arteries are best imaged during diastole, when 
there is little cardiac motion. Thus, the ECG triggering is done during end systole or early 
diastole. In clinical practice, 75% of the patient’s R-R interval is most favorable for cardiac 
imaging. Factors such as heart rate irregularities, and tachycardia may necessitate the use of 
values anywhere between 40-80% of R-R interval for cardiac triggering. 
EBT is an ultrafast single slice, high resolution CT scan. Like any form of CT scans, the X-ray 
source-point moves along a circle in space around an object to be imaged. In EBT, however, 
the X-ray tube itself is large and stationary, and partially surrounds the imaging circle. 
Rather than moving the tube itself, the electron-beam focal point (and hence the X-ray 
source point) is swept electronically along a tungsten anode in the tube, tracing a large 
circular arc on its inner surface. This motion can be very fast. The resultant scan provides 3 
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mm thick continuous nonoverlapping slices with an acquisition time of 100 msec/tomogram 
in a prospective manner (Agatston et al., 1990; Callister et al., 1998a).  
As opposed to EBT, MDCT is capable of acquiring clinical images of the heart with 
multislice imaging technology that captures up to 64 simultaneous anatomical slices of 0.5 
mm through an advanced 64-row data acquisition system in a single gantry rotation. In 
addition, the system’s sensitivity and accuracy are enhanced with a process called isotropic 
scanning. This fast scanning capability allows important diagnostic information concerning 
the heart to be obtained within a single breath-hold, less than ten seconds, and a CT 
angiogram can be imaged within 15 seconds. The latest generation of MDCT scanners can 
acquire up to 320 sections of the heart simultaneously with ECG triggering in either a 
retrospective or prospective fashion. The patient lies on the CT couch, and the couch is 
advanced gradually either continuously (helical or spiral scanning) at a fixed speed or in a 
stepwise fashion (axial/conventional scanning). Figure 3 demonstrates the two scanning 
modes of MDCT. The gantry speed is up to 330 msec (Agatston, 1990). 
 
Adapted with permission from Shuman W.P. et al. Prospective versus Retrospective ECG Gating for 64-
Detector CT of the Coronary Arteries: Comparison of Image Quality and Patient Radiation Dose. 
August 2008 Radiology, 248, 431-437. 
Fig. 3. Retrospective and Prospective Gating Techniques for Coronary Computed 
Tomography Angiography. 
2.2 Calcium scoring 
Coronary calcium scans are performed using the axial mode and with prospective ECG 
gating. Either EBT or MDCT scanners can be used for this purpose. No intravenous contrast 
is necessary. Coronary calcium is diagnosed when as two or three hyperattenuated adjacent 
pixels with tomographic density of >130 Hounsefeld (HU) units for EBT and 90-130 HU for 
MDCT, are visualized within the coronary tree. The computer software then computes a 
calcium score for the patient using either the Agatston or Callister methods. The Agatston 
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method involves multiplying the calculated area of the calcification (measured every 3 mm 
slice thickness) by the CT density of the same area. Partial volume averaging artifacts could 
theoretically pose a threat to the validity of this calculation. This artifact results when the 
computer yields a CT number representative of the average attenuation of the materials 
within a voxel. Also scanning at 3 mm slice thickness overestimates the area of smaller 
lesions that are 1mm or less (Barrett & Keat, 2004). As a result, some smaller lesions receive 
higher peak values for intensity and area. Despite this theoretical concern, there is evidence 
to suggest that the Agatston score correlates well with that calculated using the Callister 
method (Callister et al., 1998a). The latter involves computing volume rather than area for 
lesions with HU density above specified threshold. This partially corrects for slice thickness 
induced artifacts. Figure 4 summarizes coronary artery calcification (CAC) score calculation. 
In comparing EBT and MDCT head to head, studies have revealed an excellent correlation 
between the two for the presence of calcium (Mao et al., 2009; Daniell et al, 2005; Budoff et 
al., 2006). This being said, there were some minor differences. Compared to EBT, MDCT had 
more motion artifacts, and also had higher mean HU for calcific lesions (p<0.001). The 
Agatston and volumetric scores were not significantly different between EBT and MDCT. 
However, the study by Mao et al used heart rate control for calcium scoring scans (Mao et 
al., 2009). Majority of centers do not routinely use heart rate control for this purpose alone, 
unless a coronary CT Angiogram is also requested. Even in the absence of heart rate control, 
Daniell et al did not report any significant difference between the two scanners. At our 
center, MDCT is routinely employed for this purpose, without heart rate control. 
Using either of the two methods described above, the computer generates a Calcium Artery 
Calcification (CAC) Score report. The report compares the patient’s calcium score to age and 
gender matched controls, and generates a percentile value for the patient in question.  
 
Fig. 4. Coronary Calcium Score (CCS) calculation in a patient with extensive coronary 
calcification 
The figure depicts extensive coronary artery calcification involving the left main and the left 
anterior descending arteries. Agatston score is calculated by multiplying the area of the 
calcification (mm2) by its density in Hounsefeld units (HU). The total calcium score is much 
higher than that for the lesion depicted. 
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2.3 Radiation dose 
Recently, significant concerns have been raised about the radiation exposure to patients 
from CT scans. Typical radiation dose from a retrospectively gated coronary CT angiograms 
(CTA) ranges from 10-18 mSv (Gopal & Budoff, 2009). With the introduction of radiation 
dose reducing techniques such as dose modulation, reduction of kilovoltage for thinner 
patients, limitation of vertical scan field and prospective gating, the exposure to radiation 
can be decreased by 80-90%. In fact, studies have reported that the use of prospective gating 
alone, without any other dose sparing techniques, cuts down radiation exposure by 70-80%. 
The typical radiation dose for a prospectively gated CTA is about 4.2 mSv (about the same 
or slightly lower than a diagnostic cardiac catheterization) (Hirai et al., 2008; De Backer et 
al., 2003).  
Although these concerns are valid for coronary CT angiograms (both prospectively and 
retrospectively gated), radiation exposure is certainly not an issue for calcium scoring. 
Radiation exposure from CCS scans alone is approximately 1 mSv from either EBT or MDCT 
scanners. This exposure is negligible, and is nearly equivalent to that from a single X ray. 
Thus, the benefit of assessing coronary calcium in at risk individuals justifies the minor risk 
of radiation exposure in most patients.  
2.4 Coronary artery calcium scoring in asymptomatic patients 
It has been proven that plaque rupture and acute coronary syndromes are generally a 
function of the total atherosclerotic burden (Kullo & Ballantyne, 2005). Since calcium is 
known to appear at an advanced stage of atherosclerosis, it has been proposed that patients 
with calcific plaques also likely have “soft” plaques that could be vulnerable to rupture. The 
co occurrence of calcific and noncalcific plaques forms the basis of using CCS as a predictor 
of acute coronary syndromes. Although CAC may not identify a vulnerable plaque per se, it 
defines a patient’s risk for coronary events by virtue of its association with total plaque 
burden (Rumberger et al., 1995; O’Rourke et al., 2000; Agatston et al., 1990). This is the very 
basis of testing asymptomatic patients for coronary calcification. Detection of coronary 
artery calcifications in this group of individuals can help direct decisions on intensity of 
lipid lowering, aspirin therapy etc. Whether this strategy is useful across all risk groups is 
questionable, and is discussed later. In the sections to follow, we review data from 
metaanalyses, observational and prospective cohort studies on prognostic value of CCS. 
2.5 Observational studies 
Several observational studies have suggested the utility of CCS in cardiac risk stratification. 
Earlier studies often focused on endpoints such as coronary revascularization. These studies 
were criticized for a lack of hard endpoints such as cardiac death, myocardial infarctions 
(MI) etc, and were thought to overestimate the prognostic value of calcium scoring (Pletcher 
et al., 2004). However, we now have more than a few studies looking at hard endpoints 
described above. Table 2 summarizes the salient findings of these studies (Arad et al., 2000, 
2005; Wong et al., 2000; Raggi et al., 2001; Kondos et al, 2003; Shaw et al., 2003; Greenland et 
al., et al, 2004; Vliegenthart et al., 2005; Taylor et al., 2005; LaMonte et al., 2005; Budoff et al., 
2007; Becker et al., 2008; Anand et al., 2006; Polonsky et al., 2010). Briefly, the study by Arad 
et al (2000) showed that among 1172 asymptomatic patients observed for 3.6 years after an 
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initial EBT screening, no events occurred in patients without coronary calcification, and in 
patients with a CAC score <100. The negative predictive value of a normal CCS scan was 
99.8% for hard cardiac endpoints. Also the authors described increasing cardiac event rates 
in individuals with a CAC score ≥80, ≥160, and ≥600. Raggi and coworkers (2001) studied 
more than 600 asymptomatic patients who underwent EBT and were then followed for 32 ± 
7 months. They showed that both the absolute CAC score and the relative score percentiles 
predicted subsequent death and nonfatal MI. Additionally, hard cardiac events occurred in 
only 0.3% of subjects with a normal CAC score, but increased to 13% in those with a CAC 
score >400. The largest observational study with the longest duration of follow up was 
reported by Budoff and colleagues (2007). They followed 25,253 patients out to 6.8 years, 
and reported relative risk ratios of 4.5 for CAC scores between 101 and 299, and 12.5 for 
scores more than 1000. Shaw and colleagues (2003) demonstrated that mortality significantly 
increased with increasing CAC score, within men and women separately as well as within 
each Framingham risk group (low, intermediate, and high-risk). This finding contradicts a 
report from Kondos et al. (2003) describing the futility of CCS in patients with low 
Framingham risk. With the exception of minor differences, most studies indicate that CAC is 
an independent predictor of CAD adverse outcome as well as of all-cause mortality after 
adjusting for traditional risk factors. It should be noted that these studies consistently quote 
impressive relative risk ratios, but when one looks at the absolute risk, the difference is not 
as impressive in majority of the studies. Also most data has been reported in Caucasian 
population. Thus, the author does advise caution in extrapolating these vivid results to one’s 
practice, and ethnically diverse patient population.   
2.6 Prospective studies and meta-analysis 
 Prospective studies have confirmed these results, and have additionally indicated an 
independent role for CCS above traditional risk factors. The South Bay Heart Watch study 
included 1196 asymptomatic patients who were observed for a median of 7.0 years, and it 
was demonstrated that the CAC score added predictive power beyond that of standard 
coronary risk factors and C-reactive protein (Greenland et al., 2004). Registry data from the 
St. Francis Heart Study, a prospective population based study of over 5000 asymptomatic 
individuals confirmed the higher event rates associated with increasing CAC scores (Arad et 
al., 2005). CAC scores >100 were associated with relative risks of 12 to 32, thus achieving 
secondary prevention equivalent event rates >2%/year (superior to FRS). The Rotterdam 
Heart Study studied CCS in a slightly older cohort, i.e. 1795 asymptomatic patients with 
mean age of 71 years (Vliegenthart et al., 2005). During a mean follow-up of 3.3 years, the 
multivariate-adjusted relative risk of coronary events was 3.1 for calcium scores of 101 to 
400, 4.6 for calcium scores of 401 to 1000, and 8.3 for calcium scores >1000. In a younger 
cohort of asymptomatic persons, the 3-year mean follow-up in 2000 participants (mean age, 
43 years) showed that coronary calcium was associated with an 11.8 fold increased risk for 
incident CAD (P <0.002) while controlling for the FRS (Taylor et al., 2005).  
Budoff and colleagues (2007) showed risk-adjusted hazard ratios of 2.2 for total mortality for 
CAC score categories of 11-100, and 12.5 for category >1000. CAC scores provided 
significant incremental information over traditional risk factors. In Europe, Becker and 
coworkers (2008) reported their data in 924 patients aged 59.4 ± 18.7 years During the 3-year 
follow-up period, the event rates for coronary revascularization, MI, and cardiac death in 
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patients with volume scores above the 75th percentile were significantly higher compared 
with the total study group, and no cardiovascular events occurred in patients with scores of 
zero. In fact, their statistical analysis demonstrated that it outperformed both PROCAM and 
Framingham models (P <0.0001), in which 36% and 34% of MIs occurred in the high-risk 
cohorts, respectively. 
The studies discussed this far did not include particularly high-risk subgroups. Anand et al 
(2006) evaluated CCS in asymptomatic diabetic patients. CAC scores were prospectively 
measured in 510 asymptomatic type 2 diabetic subjects (mean age, 53 ± 8 years; 61% men) 
without prior CVD, with a median follow-up of 2.2 years. In the multivariable model, the 
CAC score and extent of myocardial ischemia by nuclear stress testing were the only 
independent predictors of outcome. Performance analysis using receiver operative curve 
(ROC) analysis (described in detail later) demonstrated that CCS predicted cardiovascular 
events with the best accuracy, area under the curve (0.92), significantly better than the 
United Kingdom Prospective Diabetes Study risk score (0.74) and Framingham score (0.60). 
The relative risk to predict a cardiovascular event for a CAC score of 101 to 400 was 10.13, 
and it increased to 58.05 for scores >1000 (P <0.0001). Even in this diabetic population, no 
cardiac events or perfusion abnormalities occurred in subjects with CAC ≤10 Agatston units 
up until 2 years of follow-up. These results emphasize the value of screening for subclinical 
disease in diabetics who often do not feel regular symptoms of coronary artery disease and 
thereby labeled as “asymptomatic”.  
Combining results of several studies, a meta-analysis of six trials was published in the 
ACC/AHA consensus document on CCS (Greenland et al., 2007). The meta-analysis 
reported a relative risk ratio of 4.3 for any measurable calcium, as compared with zero CAC 
score, thus implying a four-fold increase in the 3-5 year risk. Also, the annual incidence of 
coronary events increased with increasing tertiles of CAC scores (see fig 5). Although critics 
tend to point to limitations such as study generalizability of self-referral cohorts, validity of 
the risk factor measures and risk of test-induced bias, the meta-analysis still remains a stellar 
piece of evidence supporting the prognostic value of coronary artery calcium scoring. 
 
 
Adapted with permission from Greenland et al. JACC Vol. 49, No. 3, 2007. ACCF/AHA Expert 
Consensus Document on Coronary Artery Calcium Scoring January 23, 2007:378 – 402 
Fig. 5. Annual incidence of Coronary Artery Disease related events in different tertiles of 
Coronary Calcium Scores. 
www.intechopen.com
 
Vascular Inflammation: A New Horizon in Cardiovascular Risk Assessment 
 
113 
 
Author (Year) Study and  
Population 
Follow Up 
(Years) 
Number of Events Results 
Arad et al  
(2000) 
Observational  
N = 1172 
3.6 15 nonfatal MI, 21 
revascularizations,  
3 deaths 
OR of 20 for CAC 
scores ≥160  
Wong et al  
(2000) 
Observational  
N = 926 
3.3 6 nonfatal MI, 20 
revascularizations,  
2 CVA 
Overall, patients with 
CAC score ≥271 had a 
risk ratio of 9 for a 
CAD event. 
Raggi et al  
(2001) 
Observational  
N = 676 
2.7 21 nonfatal MI, 9 
deaths 
OR of 22 for cardiac 
events for CAC score 
> 90 percentile 
Kondos et al  
(2003) 
Observational  
N = 5635 
3.1 37 nonfatal MI, 166 
revascularizations,  
21 deaths 
RR of 124 for cardiac 
events in men; 
incremental 
prognostic value of 
CCS 
Shaw et al  
(2003) 
Observational  
N = 10,377 
5 249 all-cause mortality CAC score an 
independent predictor 
of mortality with RR 
4.0 for score of 401-
1000 
Greenland et al 
(2004) 
Prospective  
N = 1312 
7 68 nonfatal MI, 16 
deaths 
RR of 3.9 for CAC 
score >301 
CAC score 
incremental to FRS  
Arad et al  
(2005) 
Prospective  
N = 4613 
4.3 40 nonfatal MI, 59 
revascularizations,  
7 CVA 
RR for CAD events 
with CAC >100 11. 
CCS superior to FRS 
in prediction of 
cardiac events 
Vliegenthart et al 
(2005) 
Prospective  
N = 1795 
3.3 40 nonfatal MI, 38 CVA RR >8, for CAC scores 
>1000 regardless of 
FRS 
Taylor et al  
(2005) 
Prospective  
N=1983 
3 9 ACS events CAC had an 
independent12-fold 
increase in RR.  
LaMonte et al 
(2005) 
Retrospective  
N=10746 
3.5 81 MI/CAD death,  
206 revascularizations 
Increasing cardiac 
event rates with 
higher CAC scores 
Anand et al  
(2006) 
Prospective N= 
510 (diabetics)  
2.2 Total 22 events (cardiac 
and cerebral) 
Rate of death or MI 
increased by CAC 
categories  
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Budoff et al  
(2007) 
Observation referral-
based 
N = 25,253 
6.8 510 all-cause deaths Rate of death or MI 
increased by CAC 
categories  
Detrano et al 
(2008) 
Prospective  
N=6,814 
3.4 162 CAD events  FRS-adjusted risk 28% 
higher with CAC 
scores doubling.  
CAC predictive in all 
ethnic groups 
Becker et al  
(2008) 
Prospective  
 
3.3 179 (65 cardiac death, 
114 MI) 
CAC score ≥75th 
percentile associated 
with higher 
annualized event rate 
for MI. No cardiac 
events in patients 
with CAC = 0. 
(CAC: Coronary Artery Calcium, CAD: Coronary Artery Disease, CVA: Cerebrovascular Accident, FRS: 
Framingham Risk Score, MI: Myocardial infraction, OR: odds Ratio, RR: relative risk)  
Table 2. Clinical Trials summarizing data on Coronary Calcium Scoring. 
2.7 Independent prognostic value of CAC scores over cardiac risk factors 
Several authors in the preceding section have described an incremental role for CCS. Wong 
and colleagues (2000) showed that the CAC score severity predicted subsequent 
cardiovascular events independent of age, gender, and patient risk factor profile. Recent 
reports have included univariable and multivariable models that have evaluated the 
independent contribution of CAC in models evaluating risk factors or the FRS. The CAC 
score strongly predicted mortality, with 43% additional predictive value beyond risk factors 
alone (Greenland et al., 2004). In the St. Francis Heart Study, both univariable and 
multivariable models supported CAC scores as independent predictors of CAD outcome 
above and beyond traditional risk factors (Arad et al., 2000). Of note, CAC scores were also 
predictive of outcome in a multivariable model containing high-sensitivity C-reactive 
protein, a relatively newer marker for CAD (Taylor et al., 2005), similar to a previous report 
by Park et al. (Park et al., 2002). Other authors have evaluated the prognostic contribution of 
CCS in multivariable models that controlled for risk factors such as a family history of 
premature CHD or body mass index, that are not in the FRS, and proved CCS to be 
independently predictive in these settings too (LaMonte et al., 2005; O’Malley et al., 2003.  
2.8 Coronary calcium scoring: Complementary to Framingham scores and global risk 
assessment? 
Since CCS has shown to have incremental value over risk factors, the next step is to assess 
whether it can be integrated in to risk assessment algorithms. The concept of Bayesian 
theory provides a framework to evaluate the expected relationship between the predictive 
values of CAC score in individuals with low- to high-risk FRS. As dictated by Bayesian 
theory, a test’s post-test likelihood of events is partially dependent upon a patient’s pretest 
risk estimate. Thus, for patients with a low risk FRS very few events would be expected 
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during follow-up and the resulting post-test risk estimate for patients with an abnormal 
CAC score would be expected to remain low. Not surprisingly, several reports have 
documented the futility of CAC score in risk prediction for low-risk populations (Kondos et 
al., 2003; Greenland et al., 2004). Such studies demonstrate the importance of selecting 
optimal cohorts for whom CAC testing will be of greater value. In addition, the recent data 
provide support for the concept that use of CAC testing is most useful in terms of 
incremental prognostic value for populations with an intermediate FRS (Redberg et al., 
2003). In a secondary analysis of patients with an intermediate FRS from 4 reports 
(Greenland et al., 2004; Arad et al., 2005; Vliegenthart et al., 2005; LaMonte et al., 2005), 
annual CAD death or MI rates were 0.4%, 1.3%, and 2.4% for each tertile of CAC score 
where scores ranged from less than 100, 100 to 399, and greater than or equal to 400, 
respectively. From this analysis, intermediate-risk FRS patients with a CAC score greater 
than or equal to 400 would be expected to have coronary event rates that place them in the 
CAD risk equivalent status i.e >20% event rate in the next ten years. 
One way to determine additive utility of a new test is through the use of Receiver Operative 
Curve (ROC) analyses. The ROC curve is a plot of true-positive rate versus false-positive 
rate over the entire range of possible cutoff values. The area under the ROC curve (AUC) 
ranges between 1.0 for the perfect test and 0.5 for a useless test. Studies comparing 
predictive capacity of conventional and newer biomarkers for prediction of cardiovascular 
events consistently demonstrate that adding a number of newer biomarkers (such as C-
reactive protein, interleukins, and other proposed risk stratifiers) change the C-statistic by 
only 0.009 (P = 0.08). Such small changes such as these in the C-statistic suggest rather 
limited improvement in risk discrimination with additional risk markers. The costs involved 
in implementing the use of such biomarkers may not be justified by the magnitude of the 
observed benefit. However, CAC scanning has been shown to markedly improve the C-
statistic in the studies described above, suggesting robust improvement in risk 
discrimination (Anand et al 2006; Budoff et al 2007). 
2.9 Calcium scoring in symptomatic patients 
This far, we have discussed the utility of CCS in asymptomatic patients. Researchers have 
investigated the role of CCS in symptomatic patients also. If a patient does not have 
coronary artery calcification, it would be very unlikely that they have high grade obstructive 
CAD. However, once calcium is discovered, theoretically, one cannot definitively opine if 
the plaque is obstructive or not. Nevertheless, this topic has been a target of active research. 
Trials investigating this subject have studied symptomatic patients referred for coronary 
angiography. 
A meta-analysis including 3683 patients from 16 studies was performed to evaluate the 
diagnostic accuracy of coronary calcium scoring (O’Rourke et al., 2000). The entry criteria 
included diagnostic catheterization for patients without prior history of coronary disease or 
prior cardiac transplantation. Patients were symptomatic and referred to the cardiac 
catheterization laboratory for exclusion of obstructive CAD. On average, significant 
coronary disease (defined as greater than 50% by some or 70% luminal stenosis by others on 
coronary angiography) was reported in 57.2% of the patients. Presence of CAC was reported 
on average in 65.8% of patients. The odds of obstructive CAD were found to be elevated 20-
www.intechopen.com
 
Cardiovascular Risk Factors 
 
116 
fold with a positive CAC. Additionally, higher coronary calcium scores were associated 
with higher degrees of obstructive coronary artery disease.  
Similar to data in asymptomatic patients, some other authors have described the 
independent predictability of CAC in symptomatic patients. A large case series by Guerci et 
al (1998) found that coronary calcium score of greater than 80 (Agatston score) was 
associated with increased likelihood of obstructive coronary artery disease regardless of the 
number of risk factors. Also, the series by Kennedy et al (1998) clearly reported that in their 
multivariate analyses, only male sex and coronary calcium score were significantly related 
to the extent of angiographic disease. The ROC analysis for CAC showed a much larger area 
under the curve, as compared to conventional risk factors, thus establishing its role as a 
disease discriminator.  
2.10 CAC in comparison to other tests for diagnosis of coronary artery disease 
As a new test for CAD, it is important to assess and compare CCS to the currently accepted 
modalities for CAD diagnosis. Schermund et al (1999) compared EBT derived CAC 
measurement to nuclear stress tests using technetium in a cohort of 308 symptomatic 
patients referred for cardiac catheterization. They found a strong association of CAC score 
with perfusion defects on Single Photon Emission Computed Tomography (SPECT) scans 
and angiographically obstructive CAD. This association remained significant after excluding 
the influence of interrelated risk factors and SPECT variables. 
Other authors have reported similar results using thallium exercise stress testing (Kajinami 
et al., 1995; Yao et al., 1997). In fact, a study by Shavelle et al (2000) indicated that CAC 
might be more accurate for diagnosis for CAD. The relative risk for obstructive CAD in this 
study was 4.43, and was significantly higher than that for treadmill ECG (1.72) or 
technetium stress (1.96). The overall accuracy of CAC was 80%, as opposed to 71 and 74% 
for exercise treadmill ECG and technetium stress respectively. When combined with an 
abnormal treadmill ECG response, CAC was found to be 83% specific for obstructive CAD. 
He et al (2000) suggest a complementary role for CCS based on their finding of a threshold 
phenomenon. In their study, no myocardial hypoperfusion was noted in patients with CAC 
less than 100, and a marked increase in perfusion abnormalities with increasing CAC scores. 
If indeed, the absence of coronary calcium in symptomatic patients can exclude obstructive 
disease, it can possibly be used in the triage of patients with chest pain in the emergency 
rooms in the future. Some groups have looked at this possibility, and although their results 
favor CAC as a triage tool (Georgiou et al., 2001; McLaughlin et al., 1999), the author 
personally has some concerns about adopting this paradigm as a standard of care, at least 
for now. This is mainly because of small sample sizes of these studies, and the fact that it 
may not be safe to discharge every patient with absent coronary calcifications. Some of these 
patients could have noncalcified soft plaques that may be prone to rupture. Absence of 
coronary calcification may lead to a false sense of security in such patients, and they may be 
discharged. A small proportion of these patients could develop a full-blown acute coronary 
syndrome outside of hospital settings. The medico-legal implications of such mishaps are far 
from few. In our opinion, until further data become available, CAC scoring should not be 
recommended as a triage tool in the emergency room setting. This issue is further elaborated 
in the section on absent coronary artery calcifications in CAD. 
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2.11 Using CCS in patients with established CAD 
While there is limited utility to CCS in patients with documented CAD, a recognized use of 
CAC screening is to track atherosclerotic changes over time by serial measurements. A large 
prospective study was designed to evaluate the impact of aggressive lipid-lowering and 
antioxidant therapy on the progression of CAC. The study included 4613 asymptomatic 
persons between 50 to 70 years of age, with coronary arteries EBT scanning at baseline and 
again at 2 years and 4.3 years (Arad et al, 2005). Whereas the intervention did not seem to 
significantly affect progression of CAC, it was noted that patients who sustained a coronary 
event demonstrated a median increase in CAC score of 247 as compared to a CAC score 
increase of 4 in those who did not sustain a coronary event. Multiple logistic regressions 
demonstrated that 2-year change in calcium score (P = 0.0001) was significantly associated 
with subsequent CAD events. Increasing calcium scores were seen to most strongly correlate 
with coronary events in this study, as in another observational study by Raggi et al. (2004). 
 Since statins are known to stabilize coronary artery plaques, one would expect that 
coronary calcification would not progress, and if anything, regress with aggressive statin 
therapy. However, the results of clinical trials have been controversial in this regard. In a 
retrospective study, Callister and associates (1998b) demonstrated a 45% slowing in the rate 
of CAC progression in patients receiving statins. Budoff and coworkers (2000), in a 
prospectively designed study, demonstrated a 61% decrease in the rate of CAC score 
progression in dyslipidemic patients on statin therapy. Similarly, Achenbach and colleagues 
(2002) showed that with a standard dose of 0.3 mg/day of open-label cerivastatin in 
dyslipidemic patients, the median annual relative increase in CAC scores was 25% during 
the untreated period before study entry versus 9% during the treatment period (P <0.0001). 
Reduction of CAC score was most pronounced in those patients who achieved an LDL level 
<100 mg/dL. 
On the other hand, at least three randomized controlled trials have failed to replicate these 
results. The SALTIRE trial (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on 
Regression) randomized 102 patients to atorvastatin or placebo and assessed CAC 
progression during an average follow-up of 2 years. Despite a significant reduction in LDL 
and C-reactive protein levels, there was a insignificant increase in percentage CAC 
progression (Houslay et al., 2006). Schermund and coworkers (2006) also failed to show 
reduced progression of CAC in asymptomatic patients randomized to 80 mg of atorvastatin, 
despite a 20% reduction in LDL level as compared to the group receiving 10-mg atorvastatin 
during one year of follow up. Similarly, the BELLES (Beyond Endorsed Lipid Lowering with 
EBCT Scanning) study, which randomized hyperlipidemic postmenopausal women to 
atorvastatin 80 mg or pravastatin 40 mg, found no effect on CAC progression in either arms. 
Although atorvastatin reduced LDL concentration by 47% ± 20% and pravastatin reduced 
LDL by 25% ± 19%, there was no significant decrease in CAC progression after 12 months, 
and rather, a statistically insignificant increase of 15% and 14% in CAC scores in the 
atorvastatin and pravastatin arms, respectively (Raggi et al., 2005). The authors were unable 
to justify this increase in CAC scores despite LDL reduction.  
Based on the conflicting data, the ACC/AHA guidelines do not recommend following CAC 
scores longitudinally to track coronary atherosclerosis over time (Greenland et al., 2007). 
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2.12 Absence of coronary artery calcium and its implications 
So far, we have reviewed data on the presence and absence of coronary calcium in 
symptomatic and asymptomatic cohorts. It appears that absence of CAC reliably excludes 
obstructive coronary disease in asymptomatic and selected symptomatic individuals. Also 
the absence of coronary calcium appears to be associated with a low cardiovascular event 
rate, suggesting that less aggressive pharmacotherapy may be acceptable in this population. 
However, published event rates for individuals with zero CAC vary, probably because of 
differences in baseline risk, follow-up period, and very different endpoints in studies.  
Overall, absence of coronary calcium appears to be favorable in terms of prognosis for 
coronary events. However, we do need to elaborate on the few patients with coronary artery 
disease, who are missed by CCS. In a cohort of asymptomatic middle-aged individuals, 
Blaha et al. (2009) observed that relatively more coronary events occurred among diabetics 
and smokers, even in the absence of CAC. The likely mechanisms include non-calcified soft 
plaques, rapid development of atherosclerosis, and plaque destabilization. Even so, whereas 
the relative risk of events is higher in the presence of low CAC, the absolute event rate 
remains low. Thus, in an appropriately selected non–high-risk patient, the absence of CAC 
can likely be used as a rationale to emphasize lifestyle therapy, while refraining from 
expensive preventive pharmacotherapy, and frequent cardiac imaging or testing. 
Given the low 10-year risk in this population, a drug such as a statin that produces a 30% 
relative risk reduction would have to be given to more than 300 patients for 10 years to 
prevent one death i.e. number needed to treat (NNT) is approximately 333 for 10 years 
(Blaha et al., 2009). Although current guidelines do not recommend that preventive 
therapies such as lipid-lowering medications be stopped or dosed lower in the absence of 
CAC, data from the aforementioned studies suggest that aggressive management in this 
cohort is probably not warranted if one does not qualify according to NCEP guidelines. This 
strategy will allow those with absent CAC to follow healthy lifestyle modifications with 
little or no medical therapy, whereas intense therapy is focused on a population of patients 
with an actual higher risk of events demonstrated by atherosclerotic burden on CCS. Again, 
in implementing this standard of care, one needs to remember the caveat about smokers and 
diabetic patients described above. 
The ACC/AHA guidelines echo these results, recommending against invasive diagnostic 
procedures or hospital admission in patients with absent CAC (Greenland et al., 2007). The 
ACC/ASNC appropriateness criteria also mention that the absence of CAC generally 
precludes the need for assessment by myocardial perfusion imaging (Brindis et al., 2005). 
This strategy can significantly cut down radiation exposure and coronary angiography 
related complications. 
2.13 Applying coronary calcium screening in every day life: The practicalities and 
challenges 
2.13.1 Is calcium scoring valid across various ethnicities and races? 
Demographic data suggest that African American patients have lower incidence of coronary 
artery calcifications despite a higher overall prevalence of coronary artery disease (Greenland 
et al., 2007). Most literature on CCS has been described in white populations. Two studies have 
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addressed the value of CAC in other ethnic groups. First, Nasir and coworkers (2007) in nearly 
15,000 ethnically diverse self-referred patients assessed the role of CAC for the prediction of 
all-cause mortality. In comparison of prognosis by CAC scores in ethnic minorities, relative 
risk ratios were highest for African Americans, with scores ≥400 exceeding 16.1 (P < 0.0001). 
Hispanics with CAC scores ≥400 had relative risk ratios from 7.9 to 9.0; Asians with CAC 
scores ≥1000 had relative risk ratios 6.6-fold higher than those of non-Hispanic whites (P 
<0.0001). The second study to address this question is the prospective Multi-Ethnic Study of 
Atherosclerosis (MESA) study by Detrano et al., (2008). MESA was designed to investigate 
the prevalence and progression of subclinical CAD in a population-based sample of 6814 
men and women between 45 to 84 years of age. The cohort was selected from six United 
States field centers and included approximately 38% white, 28% African American, 23% 
Hispanic, and 11% Asian (primarily of Chinese descent) patients. Their results indicated that 
when compared with whites, the relative risks for having coronary calcification were 0.78 
(95% CI, 0.74 to 0.82) in blacks, 0.85 (95% CI, 0.79 to 0.91) in Hispanics, and 0.92 (95% CI, 0.85 
to 0.99) in Chinese. Despite this difference in prevalence of CAC, the predictive value of 
coronary calcium in various ethnic groups remains valid. These results strongly support the 
role of CCS as a global coronary event risk stratifier.  
2.13.2 Is CCS equally predictive in both men and women? 
Women develop atherosclerosis about 10 years later than men. The appearance of coronary 
calcium tracks with this later onset of CAD. Thus cut off values for CAC scores are different 
in men and women. However, these differences start to diminish after the age of sixty years. 
Premenopausal women generally have a low likelihood of obstructive coronary artery 
disease and vulnerable plaques compared to age matched men. Premenopausal women who 
have any degree of CAC before sixty years of age are at much higher risk of coronary events 
and deserve particular attention to aggressive lipid therapy and risk factor modification. 
These gender differences highlight the importance of age and gender specific reference 
points for CAC scoring (Hoff et al., 2001). In this regard, one also needs to remember that we 
presently do not have any guidelines about applying these scores to younger women who 
have been rendered menopausal iatrogenically via surgical hysterectomy or oophorectomy. 
Due to small numbers, this cohort has not been systematically studied yet. It is unclear 
whether these women should be treated as though they have the same level of risk as their 
age matched male controls.  
2.13.3 Is CAC scoring valid in end stage renal disease patients? 
It is well known that the subset of patients with end stage renal disease, especially those on 
hemodialysis have a higher prevalence of coronary artery calcification. Although this cohort 
as a whole is at higher risk for coronary events, one cannot use coronary artery calcifications 
to prognosticate this group in the same way as patients without renal disease. Some studies 
suggest that such patients develop calcification of the tunica media as opposed to the typical 
intimal calcification associated with atherosclerotic plaques (Moe et al., 2002). The role of 
medial calcification remains to be explored in CAD. Studies have reported conflicting data 
about correlation between coronary calcium detected on CT scanning and luminal 
narrowing on coronary angiography (Haydar et al., 2004; Sharples et al., 2004). In the 
absence of firm recommendations in this cohort, it is best to individualize care to each 
patient as much as possible. 
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2.13.4 Who is an appropriate patient for CCS? 
The ACC/AHA consensus document on CCS mentions “it may be reasonable to consider 
use of CAC measurement in asymptomatic individuals who are at intermediate risk by the 
FRS” (Greenland et al., 2007pp 378-402). Such individuals are most likely to be reclassified to 
a higher risk status on the basis of high CAC score, thus modifying subsequent patient 
management. However, the committee did not find enough evidence for the utility of CAC 
testing in risk stratification of those considered at low risk as well as of those considered at 
high risk for CAD in the next 10 years. 
Patients with a 10-year risk >20% already qualify for aggressive lipid-lowering management 
with optional LDL-C goals of <70 mg/dL, and further CAC testing may not change 
treatment goals. The current guidelines do not recommended CAC testing for those with a 
10-year estimated risk of <10% (low risk). However, by current criteria, most non-diabetic 
women who are younger than 60 years would not be candidates for further risk 
stratification with CAC testing. This approach will exclude a large number of women at 
higher risk for CAD from CAC testing. One should remember that those at <10% 10-year 
risk of CAD are frequently at significant longer term risk of CHD, particularly those women 
with a family history of premature CAD. Since family history of premature CAD does not 
factor into most global risk algorithms, it may be advisable to screen a subset of women with 
low 10-year risk with CAC if they have family history of premature CAD. At least 25% of 
individuals with family history of premature CAD have significant CAC. Clinical studies 
have strongly supported family history of premature CAD to be an independent risk factor 
associated strongly with higher burden of subclinical atherosclerosis. Nasir and coworkers 
(2007) demonstrated that among those with premature family history of CAD (especially 
with sibling history), nearly one-third to one-quarter of self-referred patients with no or one 
CAD risk factor had CAC ≥100. 
Another way to work around this problem may be to look for alternative definitions of the 
“intermediate risk” category. The 2003 American College of Cardiology Bethesda 
Conference on atherosclerosis imaging defines “intermediate-risk groups” as those at 6% to 
20% 10-year risk, as opposed to FRS, which defines intermediate risk as 10-20% 10-year risk 
(Wilson et al., 2003). By this definition, more higher risk women would be placed in the 
intermediate-risk group, and thus qualify for risk factor modification, especially regarding 
LDL-C control, aggressive preventive strategies, such as statin, aspirin, and possibly blood 
pressure–lowering therapies if they additionally have increased levels of CAC. The 
recommendations involving low FRS risk category and women with family history of 
premature CAD were not incorporated in the 2007 consensus document on CCS. The author 
himself uses these pearls in clinical practice and looks forward to them being integrated in a 
future consensus document from the ACC/AHA. 
2.14 Does CAC scoring improve healthy life style adherence and medication 
compliance? 
Some working groups have demonstrated that the discovery of any calcium on a CAC scan 
independently lead to initiation of aspirin and/or statin therapy by physicians (Wong et al., 
1996). The same group also demonstrated that initiation of healthful lifestyle changes, 
including losing weight and decreasing dietary fat often accompanied an abnormal CAC 
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scan. Although the initiation of appropriate lifestyle and pharmacotherapy by physicians 
correlated with abnormal CAC scores, it is still unclear whether routine atherosclerotic 
imaging improves medication adherence. Kalia et al (2006) reported that in a study of 505 
asymptomatic individuals that continuation of lipid-lowering medication was lowest (44%) 
among those with a CAC score in the first quartile (0-30), whereas 91% of individuals with a 
CAC score in the fourth quartile (>526) adhered to lipid-lowering medication. In 
multivariable analysis, after adjustment for other cardiovascular risk factors, higher baseline 
CAC scores were strongly associated with adherence to statin therapy. Most data in this 
regard seem to be coming from only one group of investigators. Moreover, a randomized 
clinical trial assessing the effects of CAC scanning on estimated risk of CAD after 1 year, 
determined by changes in FRS, found no difference in mean absolute risk change in 10-year 
FRS comparing the groups who received CAC score results with those who did not. In this 
study, the prevalence of CAC was fairly low (15%), with generally low CAC scores even in 
those with CAC. It is possible that the study was not powered enough to detect the 
difference between the study groups (O’Malley et al., 2003).  
2.15 Is this technology cost effective? 
Establishing cost effectiveness of diagnostic tests is quite challenging. To establish 
effectiveness, CAC measurement has to be shown to enhance quality of life, prolong life or 
both. While this is feasible for therapies having randomized control trials, no such studies 
exist for CAC measurement (Douglas & Ginsburg, 1996). 
In the absence of clinical trial data, cost effectiveness is approached with simulations in 
which decisions, test results and outcomes are estimated with as much information from 
medical literature. Despite significant challenges, three studies have attempted to study cost 
effectiveness of CAC scoring (O’Malley & Greenberg, 2004; Taylor et al., 2005; Shaw et al., 
2003). Most studies assessing cost effectiveness of diagnostic modalities use the Incremental 
Cost Effectiveness Ratio (ICER) as a measure of cost effectiveness. ICER is defined as the 
ratio of the change in costs secondary to an intervention/test (compared to the alternative, 
such as doing nothing or using the best available alternative treatment) to the change in 
effects of the same (O’Malley & Greenberg, 2004). O’Malley and colleagues (2004) were able 
to demonstrate an ICER of $86752. The Prospective Army Coronary Calcium project found 
an ICER of $31,500 (Taylor et al., 2005) and Shaw et al (2003) demonstrated an ICER of 
$500,000 with estimated coronary risk of <0.6% per year, $42,339 for an incidence of 1%, and 
$30742 for an incidence of 2% per year. The consensus committee felt that neither of these 
models were strong or grounded enough to justify establishing a policy at this time. 
In our opinion, although the proposed cost effectiveness models are weak, their respective 
authors do offer a valid argument. The basis of their assertion is that both noninvasive 
testing and invasive angiography rates are low in individuals with low CAC scores. In the 
absence of CCS data, this patient population will be subjected to functional testing such as 
myocardial perfusion assessment, and possibly even invasive coronary angiography, both of 
which drive medical costs up significantly. With its valuable attributes of very little 
radiation exposure, strong risk stratification evidence, and relative inexpensiveness, CCS 
appears to be a cost effective alternative in cardiovascular care. Figure 6 summarizes the 
merits of CAC scoring as an ideal risk stratifier and an economically feasible alternative.  
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Fig. 6. Clinical (A) and Economic (B) Attributes of Coronary Calcium Scoring (CCS) 
3. Other markers for CAD 
After the extensive discussion on calcium scoring and its role in assessment of CAD, we will 
now briefly discuss other novel risk markers for CAD. 
3.1 C-reactive protein 
3.1.1 Historical background and function 
C-reactive protein (CRP) is a nonspecific marker of inflammation. C-reactive protein (CRP) 
was first described by the laboratory of Oswald Avery at the Rockefeller Institute in New 
York (Ghose, 2004). It was tested for an association with cardiovascular disease when 
inflammation was implicated as the culprit in the pathogenesis of atherosclerosis (Ross, 
1999). CRP occurs in two forms, a pentameric (pCRP) form and a monomeric (mCRP) form 
(Eisenhardt et al, 2009a). The pentameric form is produced by hepatocytes as an acute phase 
reactant, elevating up to a 1,000-fold within 24-72 hours in response to infection, 
inflammation and tissue injury (Pepys & Baltz, 1983). Monomeric CRP is believed to be 
derived from dissociation of pCRP (Eisenhardt et al., 2009b) and possibly produced in 
extrahepatic cells such as smooth muscle in arterial walls, adipose tissue and macrophages 
(Yasojima et al., 2001).  
Interestingly, pCRP is believed to promote both inflammatory and anti-inflammatory 
effects. There is even considerable data suggesting that pCRP may have vasculoprotective 
potential. mCRP however, has been documented to directly induce expression of VCAM-1 
and to play a key role in the promotion of platelet aggregation (Eisenhardt et al., 2009) . Fig 
7 summarizes the vascular inflammatory process. 
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Adapted with permission from: Eisenhardt SU, Thiele JR, Bannasch H et al. C-reactive protein: how 
conformational changes influence inflammatory properties. Cell Cycle 2009; 8:23, 3885-3892. 
Fig. 7. Role of CRP in vascular inflammation Dissociation and pro-inflammatory effects of 
mCRP in the peripheral circulation. CRP circulates as a disc shaped pentamer and is 
dissociated by its exposure to bioactive lipids on cell membranes of activated platelets and 
apoptotic/necrotic cells. The resulting mCRP then exerts its pro-inflammatory effects that 
are depicted in the figure.  
3.1.2 Nonspecific CRP 
The controversy with CRP stems from its nonspecific nature. A great degree of variability 
was noted in a study in which serial measurements of serum CRP were obtained in 159 
patients with stable ischemic heart disease. In this trial, risk stratification was performed 
using 3 risk categories (CRP <1, 1-3 and >3mg/L). In this process, 40% of patients changed 
risk categories between the first and second measurements (Ockene et al., 2001). Even a 
minor inflammatory ailment such as an upper respiratory tract infection can produce 
significant fluctuations in CRP levels, thus making it difficult to rely on it as a 
cardiovascular disease marker. 
Further, it is extremely difficult to assess CRP in the milieu of other chronic inflammatory 
disease such as rheumatoid arthritis or systemic lupus erythematosus, which independently 
raise CRP levels. A study by Breland and associates (2010) evaluated plasma levels of CRP 
in patients with CAD without inflammatory rheumatologic disease (IRD), CAD with IRD, 
IRD without CAD, and healthy subjects. They found that plasma levels of CRP in patients 
with CAD without IRD, CAD with IRD and IRD without CAD were significantly elevated 
relative to healthy individuals (p=0.002) . No significant difference was detected in levels of 
CRP in patients with CAD with or without IRD, and in patients with IRD without CAD. 
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Gasparyan et al (2010), in their review of the literature, noted that CRP plays a universal role 
in the enhanced atherogenesis in all rheumatologic diseases. Elevations in CRP levels have 
been linked to antiphospholipid antibodies in SLE (Feinboom & Bauer, 2005 as cited in 
Gasparyan et al., 2010) and anti-CCP in RA (del Val Del Amo et al., 2006). CRP as a 
prognostic marker for CAD in patients with IRD needs further studies with larger sample 
sizes, however preliminary data is suggestive that an elevated CRP does incur increased risk 
for CAD. A multiethnic lupus cohort study conducted in the USA determined that CRP 
independently predicted arterial events (hazard ratio [HR] 3.9, 95%CI 1.5-10.1) (Toloza et al., 
2004 as cited in Gasparyan et al., 2010). While in the UK, a cohort of RA patients with CRP 
levels >5 mg/L were found to be at risk of cardiovascular death (HR 3.9, 95%CI 1.2-13.4 for 
men and 4.22, 95% CI 1.4-12.6 for women) (Goodson et al., 2005 as cited in Gasparyan et al., 
2010). 
Cirrhosis complicates the interpretation of CRP, as it is a cause of decreased production of 
CRP from the liver. Also medications such as oral contraceptives have also been 
documented to increase CRP levels (Mackenzie & Woodhouse, 2006). In the recent years, 
high sensitivity CRP (hs-CRP) has generated significant interest among researchers. hs-CRP 
detects concentrations down to 0.3 mg/L and below, as compared to more traditional assays 
which detect in the range of 3 to 5 mg/L. hsCRP assays are used to assess cardiovascular 
risk because these tests are able to quantify CRP levels normally observed in asymptomatic 
patients (Marrow, 2011).  
3.1.3 CRP and CAD link 
The added value of high hsCRP to risk stratification was initially evaluated by Ridker and 
colleagues (Cook et al., 2006). In their model they added hsCRP to variables utilized in the 
Framingham risk score (i.e., age, total cholesterol level, high-density lipoprotein cholesterol 
level, smoking and blood pressure) in the Women’s Health Study (Cook et al., 2006). Their 
results showed only a marginal improvement in the area under the receiver operating 
characteristic curve (AUC-ROC) (Cook et al., 2006). The same group then explored whether 
risk prediction of hsCRP could be improved when used together with several other novel 
biomarkers such as hemoglobin A1c (HbA1c), homocysteine, soluble intercellular adhesion 
molcule-1, and apolipoproteins (Ridker et al., 2007). The Women’s Health Study was 
divided into a model derivation cohort (n = 16,400) and a model validation cohort (n = 8158) 
(Ridker et al., 2007). The amalgamation that produced the best fitting model consisted of 
age, systolic blood pressure, current smoking, hsCRP, parental history of MI < age 60, 
HbA1c in diabetics, apolipoprotein B-100 level, apolipoprotein A-I level and lipoprotein (a) 
levels. This algorithm was simplified for more efficient clinical utility into the Reynolds Risk 
Score (RRS) (Ridker et al., 2007) (see Table 3). The RRS reclassified 40-50% of intermediate-
risk, as predetermined by the FRS, to higher risk or lower risk. The FRS and RRS differ in 
the addition of hsCRP and parental history of MI < age 60 to the latter. However, it is 
important to point out that none of the subjects were reclassified from a low risk to a high 
risk category and vice versa, emphasizing the importance of determining prior probability 
of disease in those recommended to have further testing. The RRS was later validated in 
men. When compared to a traditional risk stratification model, the RRS reclassified 18% of 
subjects in the Physicians Health Study II, and was associated with better model fit and 
discrimination (Ridker et al., 2008a). 
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Best-Fitting Model Clinically Simplified Model 
Age  Age 
Systolic blood pressure Systolic blood pressure 
Current smoking Current smoking 
hsCRP hsCRP 
Parental history of MI <age 60 Parental history of MI <age 60 
Hemoglobin A1c (if diabetic) Hemoglobin A1c (if diabetic) 
Apo B-100 Total Cholesterol 
Apo A-I HDL-C 
Lp(a) [if apo B-100  ≥ 100]  
Adapted with permission from Ridker PM, Buring JE, Rifai N, et al. Development and validation of 
improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk 
Score. JAMA 2007; 297:611-619. 
Table 3. Reynolds Risk Score 
Most recently, evaluation of the therapeutic benefit of statin therapy in patients with LDL-C 
levels lower than 130 mg/dL, with elevated hsCRP levels greater than 2mg/L was 
examined in the Justification for the Use of Statins in Primary Prevention: an Interventional 
Trial Evaluating Rosuvastatin (JUPITER). Patients who met these criteria were treated with 
Rosuvastatin. Treatment with this therapy was associated with a 44% relative risk reduction 
in major cardiovascular events. The trial was discontinued early due to the early observation 
of clear benefit from such therapy (Ridker et al., 2008b). The Atherosclerosis Risk in 
Communities (ARIC) study was then conducted analyzing data on participants with the 
entry criteria of the JUPITER trial (Yang et al., 2009). The results of the ARIC trial suggested 
that elevated hsCRP conferred high risk regardless of LDL-C levels (<130mg/dL or ≥ 
130mg/dL) (Yang et al., 2009). 
3.2 Lipoprotein associated phospholipase A2  
3.2.1 Form and function 
Lipoprotein Associated Phospholipase A2 (Lp-PLA2) was first cloned in 1995. It is a modified 
LDL particle in which a large glycoprotein, apolipoprotein (a), is covalently bound to apo B 
by a disulfide bridge (Streyer et al., 1994). The apo(a) chain has five cysteine rich domains 
known as “kringles”. The fourth kringle is homologous is structure to the fibrin-binding 
domain of plasminogen, the plasma protein responsible for dissolving clots. This structural 
similarity unfortunately sets up a competition between Lp-PLA2 and plasminogen for 
binding sites, thus causing interference with fibrinolysis. Lp-PLA2 induces foam cell 
formation and encourages cholesterol deposition in atherosclerotic plaques (McLean et al., 
1987). Lp-PLA2 is also thought to propogate inflammation via its action on oxidized 
phospholipids and nonesterified fatty acids, both of which are capable of inducing 
expression of adhesion molecules and attracting monocytes (Caslake & Packard, 2005). 
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3.2.2 Cardiovascular risk and Lp-PLA2  
Studies have contended Lp-PLA2 as another biomarker associated with both cardiovascular 
disease and stroke (Ballantyne et al., 2004; Blake et al., 2001). The ARIC study that evaluated 
the increase in predictive risk provided by 19 markers including hsCRP showed that only Lp-
PLA2 significantly increased the AUC-ROC when added to traditional risk factors for 
cardiovascular disease (Folsom et al., 2006). The largest prospective analysis, that assessed the 
association between increased Lp-PLA2 and coronary artery disease revealed an odds ratio of 
1.60 (95% CI 1.09-1.18) for those patients with Lp-PLA2 values in the upper third tertile as 
compared to the lowest third tertile after adjusting for traditional risk factors (Bennet et al., 
2008). The best data summarizing the relationship between Lp-PLA2 and cardiovascular 
disease comes from a meta-analysis of individual patient records from 120,000 subjects in 36 
prospective studies (Erqou et al., 2009). This study was able to show that Lp-PLA2 was 
associated with a continuous risk for cardiovascular events (Erqou et al., 2009).  
3.2.3 Who should be screened? 
Although Lp-PLA2 is a valid cardiovascular disease marker, it may not be feasible to screen 
everybody for the same. Stein and Rosenson (1997) put forth some recommendations for 
screening and treatment of Lp-PLA2. Based on their recommendations, screening should 
only be performed in the following circumstances: 
1. Patients with coronary heart disease and no other identifiable dyslipidemia. 
2. Patients with strong family history of coronary heart disease and no other dyslipidemia. 
3. Patients with hypercholesterolemia refractory to therapy with LDL cholesterol lowering 
therapies. 
The last recommendation stemmed from the observation that Lp-PLA2 does not respond to 
usual the therapy for LDL-C. The Friedewald formula, which is commonly used to calculate 
LDL cholesterol, does not distinguish between Lp-PLA2, and LDL-cholesterol. Often, 
patients who present with elevated LDL may not have true LDL excess, but may instead 
have significant Lp-PLA2 accumulation (Berresen et al., 1981). Such patients may be 
“refractory”to traditional LDL lowering therapy with statins, bile acid sequestrants, fibric 
acid derivatives etc.  
3.2.4 Treatment 
The most effective treatment to reduce Lp-PLA2 levels is nicotinic acid (Carlson et al., 1989). 
Estrogen replacement therapy has also been reported to reduce Lp-PLA2 by 50% (Sacks et 
al., 1994). Apheresis is a newer therapy that has been investigated for treatment of elevated 
Lp-PLA2 (Keller, 2007).  
3.3 Apolipoprotein B 
Forty years ago Fredrickson and associates recognized that atherosclerosis is more closely 
related to the total number of apolipoprotein B (apo B)-containing particles rather than to 
LDL-C (Ridker et al., 2007). Apo B is an integral part of LDL, oxidized LDL, VLDL, and 
triglycerides (TG). It thus provides a direct measure of all circulating atherogenic 
lipoproteins (Ridker et al., 2008b). Also, measurement of LDL may sometimes be inaccurate 
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in the setting of hypertriglyceridemia, particularly in diabetic patients. The utility of Apo-B 
in cardiovascular risk stratification is discussed in the paragraphs to follow. The author and 
his working group of clinicians use this marker frequently in day-to-day practice. 
3.3.1 Combining apolipoproteins with CCS 
Having discussed the above biomarkers in detail, it is now time to deliberate on how they 
can be incorporated in to an algorithm for clinical use. At the present time, there are no 
randomized trials or guidelines describing such combinations. The thoughts and 
possibilities presented in this section of the chapter are entirely based on the author’s 
personal clinical experience. We present the risk stratification algorithm followed at our 
institution. We wish to emphasize that this approach should be considered experimental in 
the absence of evidence-based data supporting this paradigm. 
Like most clinicians, we start our patient risk assessment by calculating Framingham risk 
scores. When patients are identified to have a 10-year risk of 10-20%, particular attention is 
paid to their HDL status. When these patients have low HDL, cardiologists consider the 
possibility of premature atherosclerosis in certain subtypes of patients within this class. Two 
main categories of dyslipidemias with risk of premature atherosclerosis include Familial 
hypertriglyceridemia (High TG, Low HDL, near normal LDL; otherwise known as Type IV 
Hyperlipidemia) and Familial Combined Hyperlipidemia (high TG, high LDL, low HDL; 
otherwise known as Type IIb Hyperlipidemia). These disorders are not very uncommon, 
and such patients have high levels of small dense LDL in their circulation (Genest et al, 
1992). Particularly, the subgroup with Type IV hyperlipidemias is often clinically 
undertreated because of normal to near normal LDL levels. While lipoprotein analysis is not 
the routine standard of care for every patient at our institution, we do recommend checking 
Apo B 100 levels for further risk stratification in the class patients described above, 
particularly if they have family history of premature CAD. The apo B levels reflect their 
potential for early subclinical atherosclerosis.  
If the Apo B levels are reported to be within normal limits, further testing is not encouraged 
and annual follow up of lipid panels, along with statin therapy is advised per the NCEP 
guidelines. However, in the presence of elevated Apo B 100 levels, these patients are 
aggressively treated with statins, with or without niacin to achieve LDL goals of <70 mg/dl. 
We also follow their Apo B levels with therapy with a goal to maintain Apo B levels less 
than 80 mg/dl. In such patients, a one-time screening with coronary calcium scoring is 
offered. The rationale for this protocol is that these patients, by virtue of their small dense 
LDL particles are at much higher risk for plaque inflammation and rupture. In the absence 
of coronary artery calcifications, no further workup for CAD is recommended, and patients 
are encouraged to keep up with lifestyle modifications, while maintaining their cholesterol 
levels at those dictated by the NCEP guidelines. The detection of coronary calcium alerts the 
physician that the patient in question has already developed vulnerable plaques with silent 
plaque ruptures. This finding reinforces life style modifications and compliance 
with/modification of lipid therapy. Further, we quantify the CAC scores. The presence of 
calcium scores >100, suggests high risk for cardiovascular events, and suggests the need for 
further assessment of atherosclerotic coronary disease with either functional stress testing or 
coronary CT Angiography. In the absence of coronary calcification, the life style behaviors 
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and lipid pharmacotherapy are still recommended, and the option of repeating calcium 
scoring every 2-3 years with/ without coronary CTA is offered. 
Thus, we clinically use Apo B 100 as a surrogate for soft plaque and coronary calcification as 
a surrogate for ruptured plaques. In our experience, we do find it cost effective to avoid 
routine stress testing in the presence of normal Apo B levels and absent coronary 
calcification in asymptomatic patients even with family history of premature CAD. 
Although our data are not enough to present our thoughts in the form of a study yet, we 
have had very good success rate with detection of subclinical disease and prevention of 
acute coronary syndromes in patients with intermediate Framingham risk scores. Our group 
is working on designing an observational study to test this clinical algorithm. Figure 8 
summarizes our algorithm. 
 
 
Fig. 8. Cardiovascular Risk stratification Algorithm proposed by Hegde et al 
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3.3.2 Platelet volume as a marker of cardiovascular risk 
Although the author has focused mainly on the role of CCS and lipoproteins in this chapter, 
there are emerging data on the role of other novel markers such as platelet morphology and 
volumes as markers of cardiovascular disease. Mean platelet volume (MPV) has been 
studied as a marker of both vascular inflammation and thromboses (Gasparyan et al 2011). 
Diabetic patients have hyperactive platelets that are hyposensitive to anti aggregatory 
effects of prostacyclins and nitric oxide (Watala C. 2005). They also have higher MPV values 
as compared to normal controls. In fact, Zuberi et al have described that MPV reaches its 
highest level with increasing insulin resistance, and transition from prediabetes to diabetes, 
indicating a major increase in the level of risk. Vander Loo and colleagues have indicated 
that high MPV may herald the occurrence of an acute coronary syndrome in the near future. 
Inflammatory cytokines such as IL-6 and CRP alter the morphology of platelets released 
from the bone marrow weeks before an acute coronary syndrome. This finding could 
potentially be utilized to risk stratify asymptomatic individuals in to low, intermediate 
versus high risk groups for cardiovascular events. This idea has also been explored in the 
setting of an actual acute cornary syndrome. Pizzulli et al observed that in subgroups of 
patients with acute coronary syndromes, patients requiring percutaneous interventions had 
higher MPV as compared to those with normal MPVs. Although the concept is interesting, 
the data are not coherent cross studies. Case control studies by other authors such as Glud et 
al (1986) and Erne et al (1988) have failed to demonstrate such correlation between acute 
coronary syndromes and MPV. The role of MPV needs to be confirmed in larger clinical 
trials before we recommend its use as a cardiovascular risk stratifier. 
4. Summary and key points 
1. Subclinical atherosclerosis is the new target of early detection and treatment strategies 
to prevent acute coronary syndromes and decrease cardiac mortality. 
2. Plaque inflammation and ruptures are the culprits in acute coronary syndromes. Future 
cardiac event risk stratifiers should include biomarkers that reflect inflammation within 
vascular tree.  
3. Coronary Calcium Scoring (CCS) is a strong indicator of overall atherosclerotic burden 
in an individual. The total CCS, by virtue of its association with soft plaques, is an 
indicator of patient’s overall risk for future cardiac events. It has established validity 
across several ethnicities and age groups. 
4. CCS appears to be a strong and viable risk stratifier for patients within the intermediate 
risk category of CAD (10 year FRS 10-20%). CCS may help to redefine goals for life style 
modifications, lipid therapy and overall management for this patient population. 
5. CCS is a valid prognosticator of coronary events across multiple ethnicities including 
Caucasian, African American, Hispanic and Asian origin. 
6. CCS has limited utility and is best avoided in patients with Framingham risk scores of 
<10%, unless they have strong family history of premature CAD. CCS should also be 
avoided in patients with FRS of > 20%, since the results are unlikely to change 
therapeutic decisions anyways. 
7. CCS may be useful in symptomatic patients in the setting of equivocal stress testing 
results. 
8. There are insufficient data to support the routine use of CCS as a filter in the triage of 
symptomatic patients presenting to acute care facilities with chest pain.  
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9. Apolipoprotein and high sensitivity CRP may be combined with CCS to improve risk 
stratification in patients with intermediate Framingham scores, although the data are 
limited in this regard.  
5. Future research 
Future studies should focus on incorporating simple, yet effective novel imaging and/or 
biochemical markers in to cardiovascular risk stratification algorithms, with a goal to 
improve detection of subclinical atherosclerosis. Markers with substantial clinical evidence 
(Lp-PLA2 and Apo B) should be incorporated in to risk stratification algorithms, along with 
platelet volume indices. Clinical trials should be designed to assess the performance of such 
newer algorithms. Genetic and enzymatic markers including matrix metalloproteinases, 
interferon gamma are on the horizon, and may indeed provide incremental information that 
could improve cardiovascular care in the future. However, these markers lack sufficient 
clinical human data. Further evaluation of their efficacy and cost effectiveness is warranted. 
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